Expert panelists review the current treatment paradigm of metastatic castration-sensitive prostate cancer, including genetic testing, treatment options, patient education, and communication strategies.
EP. 1: Patient Scenario 1: A 55-Year-Old Man With Metastatic Hormone-Sensitive Prostate CancerApril 28th 2023
Key opinion leaders in the field of prostate cancer management consider optimal molecular testing practices in a patient with metastatic hormone-sensitive disease.
EP. 2: Newly Diagnosed mHSPC: Factors Used to Inform Treatment SelectionApril 28th 2023
Panelists reflect on molecular markers and other clinical factors that aid in the selection of best therapy for a patient with metastatic hormone-sensitive prostate cancer.
EP. 3: Selecting Between Doublet and Triplet Therapy in Newly Diagnosed mHSPCMay 5th 2023
Focused discussion on the respective roles of doublet and triplet regimens in patients newly diagnosed with metastatic hormone-sensitive prostate cancer.
EP. 4: mHSPC: Importance of Quality of Life and Multidisciplinary CareMay 5th 2023
After nuancing quality of life data with chemotherapy in metastatic hormone-sensitive prostate cancer, panelists consider the value of multidisciplinary care.
EP. 5: mHSPC: Assessing Patient Response and Selecting 2L Therapy at ProgressionMay 12th 2023
Shared insight on strategies to monitor patient response to therapy and select second-line treatment when hormone-sensitive prostate cancer progresses.
EP. 6: Patient Scenario 2: A 65-Year-Old Man With Metastatic Hormone-Sensitive Prostate CancerMay 12th 2023
Centering focus on a second clinical scenario of metastatic hormone-sensitive prostate cancer, key opinion leaders identify treatment options based on variations in presentation.
EP. 7: Patient Scenario 3: A 75-Year-Old Man With Metastatic Hormone-Sensitive Prostate CancerMay 19th 2023
In a third clinical scenario of metastatic hormone-sensitive prostate cancer, panelists discuss oligometastatic disease, radiation therapy, and the potential role for PSMA-PET scans.
EP. 8: Practical Considerations for Selecting and Administering Treatment in mHSPCMay 19th 2023
Expert panelists consider the possibility of taking a break from treatment given a patient’s response to therapy along with other unique management strategies in the setting of metastatic hormone-sensitive prostate cancer.
EP. 9: Future Directions in mHSPC Management: An Evolving Treatment LandscapeMay 26th 2023
Key opinion leaders in the field of prostate cancer close out their discussion by sharing excitement for future evolutions in the setting of hormone-sensitive disease management.